MS Queensland

The Department of Communities – Disability and Community Care Services will host a series of forums across Queensland to seek feedback on a 10 year support plan.

Through the 2010 Shared Visions regional forums, members of the community can give their opinion on the draft Plan for Supporting Queenslanders with a Disability.

Click here to see a list of forum dates and locations.

MS Queensland has launched a discussion forum on Facebook for people with MS and their friends, families and carers.  If you have not already, join our fan page and start participating in the conversation. 

You can ask questions, share information and meet people from around the state.  Join a current discussion or start your own topic.

Click here to visit the Facebook fan page, and then click on the "Discussions" tab.

Alemtuzumab, an IV treatment for relapsing-remitting MS, is poised for an expedited FDA review when the current Phase III trial is completed.

The FDA's Fast Track program is designed to expedite the review of new drugs that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs.

Alemtuzumab, also known as Campath and originally developed to fight cancer, could help people with MS during the early stages of the disease.

A Phase II trial has shown that Alemtuzumab reduces the risk of relapse and accumulation of disability by over 70% compared with interferon beta in patients with early relapsing-remitting MS.

Source: Genzyme